Search results
Results from the WOW.Com Content Network
Albumin-bound paclitaxel (brand name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is bound to albumin nanoparticles. Much of the clinical toxicity of paclitaxel is associated with the solvent Cremophor EL in which it is dissolved for delivery.
Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division.
A recent meta-analysis showed that when compared to Paclitaxel, nab-paclitaxel has significant beneficial effects in terms of overall response rate, progression free survival, and overall survival. [17] Side effects of nab-paclitaxel include anemia, neutropenia, alopecia, and peripheral neuropathy. Gemcitabine [16]
The FOLFIRINOX chemotherapy regimen using four drugs was found more effective than gemcitabine, but with substantial side effects, and is thus only suitable for people with good performance status. This is also true of protein-bound paclitaxel (nab-paclitaxel), which was licensed by the FDA in 2013 for use with gemcitabine in pancreas cancer. [91]
reduction of side effects of cardiac surgery: Pidilizumab [40] mab: humanized: PD-1: cancer and infectious diseases Pinatuzumab vedotin [40] mab: humanized: CD22: cancer Pintumomab: mab: mouse: adenocarcinoma antigen: adenocarcinoma (imaging) Placulumab [15] mab: human: TNF: pain and inflammatory diseases Pozelimab [35] Veopoz: mab: human: C5 ...
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed
Common side effects include diarrhea, vomiting, bone marrow suppression, hair loss, shortness of breath, and fever. [8] Other severe side effects include blood clots, colon inflammation, and allergic reactions. [8] Those with two copies of the UGT1A1*28 gene variant are at higher risk for side effects. [8]
Three early stage trials reported TNBC results in June 2016, for IMMU-132, Vantictumab, and atezolizumab in combination with the chemotherapy nab-paclitaxel. [32] In 2019, CytoDyn initiated a Phase 1b/2 trial with its humanized monoclonal antibody, leronlimab , in combination with chemotherapy following strong results in animal murine models